Treatment Action Group (TAG), the Global TB Community Advisory Board (TB CAB) and the Drug-Resistant TB Treatment Scale-up Action Team (DR-TB STAT) will host a webinar on 16 August 2018 at 10 am EDT / 4 pm South Africa / 5 pm Kenya on implementing a bedaquiline-based, injectable-free regimen for drug-resistant TB (DR-TB) in light of the new World Health Organization (WHO) policy brief on DR-TB regimens.
Dr. Nobert Ndjeka from the National Department of Health in South Africa will be talking about the South African experience as the first country to roll out this unique and less toxic regimen and how the South Africa regimen differs from the new WHO policy brief on DR-TB regimens (including advantages and disadvantages).
Eunice Omesa, the Section Head for Monitoring, Evaluation & Research from the Ministry of Health in Kenya will be talking about practical considerations countries have in order to implement a bedaquiline-based, injectable-free regimen bearing in mind the new WHO policy brief on DR-TB regimens.
Perspectives from a survivor of drug-resistant TB, and other members of civil society will also be included. TB survivor and TB PROOF management committee member Phumeza Tisile will share her experience with injectable drug-induced hearing loss and recommendations for national programs. The discussion will be moderated by Marcus Low, Spotlight editor and technical co-lead of the Global TB Community Advisory Board.
Closed captioning will be available at this link: http://www.streamtext.net/player?event=TAG. Please rearrange your screens to view the live transcription and the presentation.
Register now for the August webinar to receive your log in information.